



Please type a plus sign (+) inside this box ☒

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(To be used for all correspondence
after initial filing)

Application Number	10/079,137
Filing Date	February 20, 2002
First Named Inventor	Tony N. Frudakis
Group Art Unit	
Examiner Name	
Attorney Docket No.	210121.419C13



COPY OF PAPERS
ORIGINALLY FILED

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement; Form PTO-1449 (9 sheets) <input checked="" type="checkbox"/> Cited References (4) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53 <input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Request for Corrected Filing Receipt <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address <input type="checkbox"/> Declaration <input type="checkbox"/> Statement under 37 CFR 3.73(b) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Small Entity Statement <input type="checkbox"/> Request for Refund	<input type="checkbox"/> CD(s), Number of CD(s) _____ <input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Return Receipt Postcard <input type="checkbox"/> Additional Enclosure(s) (please identify below): _____ _____ _____
--	---	--


Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Individual Name	Julie A. Urvater, Ph.D. 50,461	 00500 PATENT TRADEMARK OFFICE
Signature		
Date	4-15-02	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date specified below.

Typed or printed name	Monica Steinborn	
Signature		Date: 4/16/02



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Tony N. Frudakis et al.
Application No. : 10/079,137
Filed : February 20, 2002
For : COMPOSITIONS AND METHODS FOR THE THERAPY AND
DIAGNOSIS OF BREAST CANCER

Docket No. : 210121.419C13

Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Sir:


In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached Forms PTO-1449. This application is a continuation-in-part and relies, under 35 U.S.C. § 120, on the earlier filing date of prior application USAN 09/924,400, filed August 7, 2001; which is a continuation-in-part of USAN 09/810,936, filed March 16, 2001; which is a continuation-in-part of USAN 09/699,295, filed October 26, 2000; which is a continuation-in-part of USAN 09/590,583, filed June 8, 2000; which is a continuation-in-part of USAN 09/577,505, filed May 24, 2000; which is a continuation-in-part of USAN 09/534,825, filed March 23, 2000; which is a continuation-in-part of USAN 09/429,755, filed October 28, 1999; which is a continuation-in-part of USAN 09/289,198, filed April 9, 1999; which is a continuation-in-part of USAN 09/062,451, filed April 17, 1998; which is a continuation-in-part of USAN 08/991,789, filed December 11, 1997; which is a continuation-in-part of USAN 08/838,762, filed April 9, 1997; which is a continuation-in-part of USAN 08/700,014, filed August 20, 1996; which is a continuation-in-part of USAN 08/585,392, filed January 11, 1996. The references listed on pages 1-8 of the attached Forms PTO-1449 were submitted to and/or cited by the Office in these prior applications and, therefore, are not required to be provided in the present application. If the Examiner wishes, copies will be provided upon request. However, the references listed on page 9 of Forms PTO-1449 were not submitted to and/or cited by the Office and are submitted herewith.

As to any reference made of record on the attached Forms PTO-1449, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other

method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,
Seed Intellectual Property Law Group PLLC


Julie A. Urvater, Ph.D.
Registration No. 50,461

JAU:mls

Enclosures:

Postcard

Forms PTO-1449 (9 Sheets)

Form PTO/SB/21

Copies of Cited References (4)


701 Fifth Avenue, Suite 6300

Seattle, Washington 98104-7092

(206) 622-4900

Fax: (206) 682-6031

D:\NrPortbl\iManage\MONICAS\275541_1.DOC

FORM PTO-1449
(REV.7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
210121.419C13APPLICATION NO.
10/079,137

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Tony N. Frudakis et al.

FILING DATE

February 20, 2002

GROUP ART UNIT

COPY OF PAPERS
ORIGINALLY FILED

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,872,237	02/16/99	Feder et al.	536	23.5	
	AB	5,811,535	10/22/98	Adamou et al.	536	23.5	
	AC	5,585,270	12/17/96	Grotendorst et al.	435	252.3	
	AD	5,523,225	06/04/96	Kraus	435	240.1	
	AE	5,516,650	05/14/96	Foster et al.	435	68.1	
	AF	5,428,145	06/27/95	Okamoto et al.	536	23.72	
	AG	5,231,012	07/27/93	Mosmann et al.	435	69.52	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AH	GB 2 273 099 A	06/08/94	Great Britain		
	AI	WO 00/61753	10/19/00	WIPO		
	AJ	WO 98/45328	10/15/98	WIPO		
	AK	WO 97/25431	07/17/97	WIPO		
	AL	WO 97/25426	07/17/97	WIPO		
	AM	WO 97/06256	02/20/97	WIPO		
	AN	WO 96/38463	12/05/96	WIPO		
	AO	WO 95/32311	11/30/95	WIPO		
	AP	WO 95/19369	07/20/95	WIPO		
	AQ	WO 95/10777	04/20/95	WIPO		
	AR	WO 91/02062	02/21/91	WIPO		


OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AS	Adams et al., Genbank Accession No. Q60347, 1993.
--	----	---

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV.7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
210121.419C13APPLICATION NO.
10/079,137

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS
Tony N. Frudakis et al.FILING DATE
February 20, 2002

GROUP ART UNIT

COPY OF PAPERS
ORIGINALLY FILED

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
BA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	BB	WO 94/11514	05/26/94	WIPO		
	BC	2,044,940A1	12/11/92	Canada		
	BD	WO 92/15680	09/17/92	WIPO		
	BE	WO 92/10573	06/25/92	WIPO		
	BF	EP0475623A1	03/18/92	Europe		


OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)


	BG	Adams et al., Genbank Accession No. Q61250, 1993.
	BH	Ahmed et al., "Characterization of a retrovirus isolated from normal mink cells co-cultivated with a dog mammary tumour," <i>J. Gen. Virol.</i> 42:179-184, 1979.
	BI	Anderson et al., "Sequence and organization of the human mitochondrial genome," <i>Nature</i> 290:457-465, 1981.
	BJ	Bakker et al., "Generation of antimelanoma cytotoxic T lymphocytes for healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells <i>in vivo</i> ," <i>Cancer Research</i> 55:5330-5334, November 15, 1995.
	BK	Bauer et al., "Identification of differentially expressed mRNA species by an improved display technique (DDRT-PCR)," <i>Nucleic Acids Research</i> 21(18):4272-4280, 1993.
	BL	Bernard et al., "Cloning and Sequencing of Pro- α 1(XI) Collagen cDNA Demonstrates That Type XI Belongs to the Fibrillar Class of Collagens and Reveals That the Expression of the Gene Is Not Restricted to Cartilagenous Tissue," <i>J. Biol. Chem.</i> 263(32):17159-17166, 1988.
	BM	Bratthauer et al., "Expression of LINE-1 Retrotransposons in Human Breast Cancer," <i>Cancer</i> 73:2333-2336, 1994.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.419C13		APPLICATION NO. 10/079,130	
<div style="display: flex; align-items: center; justify-content: center;"> <div style="text-align: center; margin-right: 10px;">  </div> <div> INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i> </div> </div>				APPLICANTS Tony N. Frudakis et al.		<div style="transform: rotate(-45deg); font-weight: bold; font-size: 1.2em;">COPY OF PAPERS ORIGINALLY FILED</div>	
				FILING DATE February 20, 2002			
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	CA	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	CB						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
					YES	NO	
	CC						
	CD						
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	CE	Byrne et al., "A Screening Method to Identify Genes Commonly Overexpressed in Carcinomas and the Identification of a Novel Complementary DNA Sequence," <i>Cancer Research</i> 55:2869-2903, 1995.					
	CF	Cease et al., "T cell clones specific for an amphipathic α -helical region of sperm whale myoglobin show differing fine specificities for synthetic peptides," <i>Journal of Experimental Medicine</i> 164:1779-1784, November 1986.					
	CG	Chai et al., Genbank Accession No. U03644, 1994.					
	CH	Charnock-Jones et al., "Extension of incomplete cDNAs (ESTs) by biotin/streptavidin-mediated walking using polymerase chain reaction," <i>J. Biotechnol.</i> 35:205-215, June 1994.					
	CI	Chen and Sager, "Differential Expression of Human Tissue Factor in Normal Mammary Epithelial Cells and in Carcinomas," <i>Molecular Medicine</i> 1(2): 153-160, 1995.					
	CJ	Cordonnier et al., "Isolation of Novel Human Endogenous Retrovirus-Like Elements with Foamy Virus-Related <i>pol</i> Sequence," <i>Journal of Virology</i> 69(9):5890-5897, 1995.					
	CK	Databank Genbank Accession No. Z34289, 1995.					
		Derks et al., "Synthesis of a viral protein with molecular weight of 30,000 (p30) by leukemic cells and antibodies cross-reacting with simian sarcoma virus p30 in serum of a chronic myeloid leukemia patient," <i>Cancer Research</i> 42:681-686, February 1982.					
EXAMINER				DATE CONSIDERED			
<p>* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant(s).</p>							

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 210121.419C13	APPLICATION NO. 10/079,137
 <p>INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)</p>		APPLICANTS Tony N. Frudakis et al.	
		FILING DATE February 20, 2002	GROUP ART UNIT

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
DA						

FOREIGN PATENT DOCUMENTS


	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
DB					


OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)


DC	Ezzell, "Cancer "Vaccines": An Idea Whose Time Has Come?," <i>The Journal of NIH Research</i> 7:46-49, 1995.
DD	Frank et al., Genbank Accession No. Q70049, 1994.
DE	GenBank Accession No. Z34289, "H. sapiens mRNA for nucleolar phosphoprotein p130," June 1, 1995.
DF	GenBank Accession Number AP001465, May 9, 2000.
DG	Gura, "Systems for Identifying New Drugs Are Often Faulty," <i>Science</i> 278:1041-1042, 1997.
DH	Haltmeier et al., "Identification of S71-Related Human Endogenous Retroviral Sequences with Full-Length <i>pol</i> Genes," <i>Virology</i> 209:550-560, 1995.
DI	Hehlmann et al., "Detection and biochemical characterization of antigens in human leukemic sera that cross-react with primate C-type viral proteins (M 30,000) ¹ ," <i>Cancer Research</i> 43:392-399, January 1983.
DJ	Herbrink et al., "Detection of antibodies cross-reactive with type C RNA tumor viral p30 protein in human sera and exudate fluids," <i>Cancer Research</i> 40:166-173, January 1980.
	Hillier et al., Genbank Accession No. H80165, 1995.

EXAMINER	DATE CONSIDERED
----------	-----------------

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.419C13		APPLICATION NO. 10/079,137	
<div style="display: flex; align-items: center; justify-content: center;"> <div style="text-align: center; margin-right: 10px;">  </div> <div> INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i> </div> </div>				APPLICANTS Tony N. Frudakis et al.			
				FILING DATE February 20, 2002		GROUP ART UNIT	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
EA							
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION			
				YES NO			
EB							
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
EC	Hillier et al., Genbank Accession No. R19532, 1995.						
ED	Hillier et al., Genbank Accession No. R55637, 1995.						
EE	Hillier et al., Genbank Accession No. R60426, 1995.						
EF	Hillier et al., Genbank Accession No. T83348, 1995.						
EG	Hillier et al., Genbank Accession No. R35308, 1995.						
EH	Hopp, T., "Computer prediction of protein surface features and antigenic determinants," <i>Molecular Basis of Cancer Part B: Macromolecular Recognition, Chemotherapy, and Immunology</i> :367-377, 1985.						
EI	Jerabek et al., "Detection and immunochemical characterization of a primate type C retrovirus-related p30 protein in normal human placentas," <i>Proc. Natl. Acad. Sci. USA</i> 81:6501-6505, October 1984.						
EJ	Kast et al., "Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins," <i>J. Immunol.</i> 152:3904-3912, 1994.						
EK	Kawakami et al., "Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression," <i>J. Immunol.</i> 154:3961-3968, 1995.						
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant(s).							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.419C13		APPLICATION NO. 10/079,137	
 <p style="margin: 0;">INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)</p>				APPLICANTS Tony N. Fridakis et al.		COPY OF PAPERS ORIGINALLY FILED	
				FILING DATE February 20, 2002			
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FA							
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
FB							
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
FC		Keydar et al., "Properties of retrovirus-like particles produced by a human breast carcinoma cell line: Immunological relationship with mouse mammary tumor virus proteins," <i>Proc. Natl. Acad. Sci. USA</i> 81:4188-92, 1984.					
FD		Leib-Mösch and Seifarth, "Evolution and Biological Significance of Human Retroelements," <i>Virus Genes</i> 11(2/3):133-145, 1996.					
FE		Leib-Mösch et al., "Endogenous Retroviral Elements in Human DNA," <i>Cancer Research</i> 50:5636s-5642s, 1994.					
FF		Leib-Mösch et al., "Genomic Distribution and Transcription of Solitary HERV-K LTRs," <i>Genomics</i> 18:261-269, 1993.					
FG		Liang et al., "Differential Display of Eukaryotic Messenger RNA by Means of the Polymerase Chain Reaction," <i>Science</i> 257:967-971, 1992.					
FH		Maeda et al., "Serum antibody reacting with placental syncytiotrophoblast in sera of patients with autoimmune diseases – a possible relation to type C RNA retroviruses," <i>Clin. Exp. Immunol.</i> 60:645-653, 1985.					
FI		Margalit et al., "Prediction of immunodominant helper T cell antigenic sites from the primary sequence," <i>The Journal of Immunology</i> 138(7):2213-2229, April 1, 1987.					
FJ		Matsubara et al., Genbank Accession No. T24124, 1995.					
EXAMINER				DATE CONSIDERED			
<p>* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).</p>							

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
210121.419C13APPLICATION NO.
10/079,137COPY OF PAPERS
ORIGINALLY FILED

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS
Tony N. Frudakis et al.FILING DATE
February 20, 2002

GROUP ART UNIT

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
GA						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
GB						

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

GC	McCombs, R., "Role of oncornaviruses in carcinoma of the prostate," <i>Cancer Treatment Reports</i> 61(2):131-132, March/April 1977.
GD	Porter-Jordan and Lippman et al., "Overview of the biologic markers of breast cancer," <i>Breast Cancer</i> 8(1):73-100, February 1994.
GE	Rammensee et al., "MHC ligands and peptide motifs: first listing," <i>Immunogenetics</i> 41:178-228, 1995.
GF	Rothbard and Taylor, "A sequence pattern common to T cell epitopes," <i>The EMBO Journal</i> 7(1):93-100, January 1988.
GG	Sette et al., "The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes," <i>J. Immunol.</i> 153:5586-5592, 1994.
GH	Smith et al., "Expression of antigenic crossreactivity to RD114 p30 protein in a human fibrosarcoma cell line," <i>Proc. Natl. Acad. Sci. USA</i> 74(2):744-748, February 1977.
GI	Spouge et al., "Strong conformational propensities enhance T cell antigenicity," <i>The Journal of Immunology</i> 138(1):204-212, January 1987.
GJ	Tsai et al., "In vitro immunization and expansion of antigen-specific cytotoxic T-lymphocytes for adoptive immunotherapy using peptide pulsed dendritic cells," <i>Critical Reviews in Immunology</i> 18:65-75, 1998

EXAMINER

DATE CONSIDERED

* EXAMINER:

Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV.7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
210121.419C13APPLICATION NO.
10/079,137COPY OF PAPERS
ORIGINALLY FILED

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS
Tony N. Frudakis et al.FILING DATE
February 20, 2002

GROUP ART UNIT

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
HA						

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES NO
HB					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)


HC	Vaczi and Toth, "Studies on antigens of C-type primate viruses and antibodies to them at patients wit myeloid leukemia and potentially preleukemic hematological disorders," <i>Arch. Geschwulstforsch</i> 50(8):769-777, 1980.
HD	Visseren et al., "CTL specific for the tyrosinase autoantigen can be induced form healthy donor blood to lyse melanoma cells," <i>J. Immunol</i> 154:3991-3998, 1995.
HE	Vitiello et al., "Analysis of the HLA-restricted influenza specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex," <i>J. Exp. Med.</i> 173:1007-1015, April 1991.
HF	Wang et al., "Detection of Mammary Tumor Virus <i>ENV</i> Gene-like Sequences in Human Breast Cancer," <i>Cancer Research</i> 55:5173-5179, 1995.
HG	Watson and Fleming, "Isolation of Differentially Expressed Sequence Tags from Human Breast Cancer," <i>Cancer Research</i> 54(17):4598-4602, 1994.
HH	Werner et al., "S71 Is a Phylogenetically Distinct Human Endogenous Retroviral Element with Structural and Sequence Homology to Simian Sarcoma Virus (SSV)," <i>Virology</i> 174:225-238, 1990.
HI	Wiley and Cunningham, "A steady state model for analyzing the cellular binding, internalization and degradation of polypeptide ligands," <i>Cell</i> 25:433-440, August 1981.
HJ	Yoshioka et al., "Pro- α 1(XI) Collagen. Structure Of The Amino-Terminal Propeptide And Expression Of The Gene In Tumor Cell Lines," <i>J. Biol. Chem.</i> 265(11):6423-6426, 1990.
HK	Critical Synergy: The Biotechnology Industry and Intellectual Property Protection, Presentation of the Intellectual Property Committee of the Biotechnology Industry Organization at the October 17, 1994, Hearing of the U.S. Patent and Trademark Office, San Diego, CA, published by the Biotechnology Industry Organization, Washington, D.C., pp. 75, 100-107.

EXAMINER

DATE CONSIDERED

* EXAMINER:

Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
210121.419C13APPLICATION NO.
10/079,137

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Tony N. Frudakis et al.

FILING DATE

February 20, 2002

GROUP ART UNIT

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
IA						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
IB						

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

IC	Gibson et al., "Novel method for real time quantitative RT-PCR," <i>Genome Research</i> 6:995-1001, 1996.
ID	Heid et al., "Real time quantitative PCR," <i>Genome Research</i> 6:986-994, 1996.
IE	Schena et al., "Quantitative monitoring of gene expression patterns with a complementary DNA microarray," <i>Science</i> 270:467-470, October 20, 1995.
IF	Yee et al., "Isolation of tyrosinase-specific CD8 ⁺ and CD4 ⁺ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus," <i>The Journal of Immunology</i> 157:4079-4086, 1996.
IG	
IH	
II	
IJ	
IK	

EXAMINER

DATE CONSIDERED

* EXAMINER:

Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).